MedTrace Logo

'MInimalist' or 'MOre Complete' Strategies for Revascularization in Octogenarians

NCT04252703 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2024-07-11

No results posted yet for this study

Summary

Older patients with co-morbidity are increasingly represented in interventional cardiology practice. They have been historically excluded from studies regarding the optimal management of NSTEACS. Though there are associated risks with invasive treatment, such patients likely derive the greatest absolute benefit from PCI. Small, though highly selective, studies suggest a routine invasive strategy may reduce the risk of recurrent myocardial infarction.

The study aims to include, as far as possible, an 'all-comers' population of patients aged 80 and above to define the optimum amount of revascularization required to achieve good outcomes and satisfactory symptom relief for this challenging cohort of patients.

Conditions

  • Multi Vessel Coronary Artery Disease
  • Ischemic Heart Disease
  • Acute Coronary Syndrome
  • Heart Diseases
  • Cardiovascular Diseases
  • Arteriosclerosis

Interventions

PROCEDURE

Percutaneous coronary intervention (PCI)

Invasive cardiac catheterization, balloon angioplasty and intracoronary stenting.

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Thomas Engstrøm, MD, PhD · Rigshospitalet, Denmark

  • Francis Joshi, MD,PhD · Rigshospitalet, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-13
Primary Completion
2022-01-01
Completion
2022-01-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04252703 on ClinicalTrials.gov